secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2025-07-15T23:59:59+00:00
Accession:  0001628280-25-034971
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine CSO Jeremy Duffield steps down effective July 15, 2025; retains as consultant through Mar 2026
--------------------------------------------------------------------------------

- Jeremy Duffield, M.D., Ph.D., FRCP, resigns as Chief Scientific Officer effective July 15, 2025.
- Company to enter Separation Agreement providing severance per his 2022 employment agreement.
- Duffield retained as consultant from July 15, 2025 through March 31, 2026.
- All outstanding equity awards continue vesting during the Advisory Period.
- No successor named in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025034971/0001628280-25-034971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025034971/prme-20250714.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-034971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer